Galenea Corp.
This article was originally published in Start Up
Executive Summary
Galenea Corp. was founded to develop new treatments for schizophrenia based on modulation of the calcineurin pathway. With funding for this long-term program secured at inception, to balance its portfolio, the start-up also licensed technology for developing a flu vaccine using RNA interference directed to conserved regions of the influenza virus--a nearer-term development proposition.